In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiho Pharmaceutical Co. Ltd.

Division of Otsuka Holdings Co. Ltd.
www.taiho.co.jp

Latest From Taiho Pharmaceutical Co. Ltd.

Evotec DNA Damage Response Spin-Out Aims For First IND-Ready Drug In 2022

Evotec’s chief science officer tells Scrip the German biotech is putting its cancer therapeutic program focused on DNA damage response into a new spin-off that aims to have an IND-ready drug in 2022.

Companies Cancer

Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate

While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.

Business Strategies Deals

Keeping Track Of Oncology: US FDA Approves Herceptin Hylecta, Reviews Darolutamide And Pexidartinib

Oncology news and highlights from our US FDA Performance Tracker.
Cancer Approvals

Interview: Janssen Builds Japan Specialty Interests But Wants Ongoing Policy Debate

Janssen’s Japan country president says while the company is committed to pursuing innovation, from a policy angle it would like to see this adequately rewarded, given the broader societal benefits it can bring. Amid increasing competition from the rest of Asia, the executive says Japan also has the chance to take a global research leadership position through appropriate reforms.

Japan Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Otsuka Holdings Co. Ltd.
  • Senior Management
  • Masayuki Kobayashi, Pres.
  • Contact Info
  • Taiho Pharmaceutical Co. Ltd.
    Phone: (81) 3 3294 4527
    1-27 Kandanishiki-Cho
    Chiyoda-Ku
    Tokyo, 101-8444
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register